Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) is a published development and funding opportunity on Contexium. The donor or funder is National Institutes of Health. Project location(s): United States. Applications close on 07 Jan 2028. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice.…
Opportunity overview
- Project name
- Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
- Donor
- National Institutes of Health
Key details
- Opportunity start date
- Opportunity end date
- Project location(s)
- United States
Summary
Frequently asked questions
What is Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)?
Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) is a published development and funding opportunity on Contexium. The donor or funder is National Institutes of Health. Project location(s): United States. Applications close on 07 Jan 2028. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice.…
Who is funding Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)?
Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) is funded by National Institutes of Health.
When is the deadline to apply for Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)?
The application deadline is 07 Jan 2028 00:00 (UTC).
Where will the Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional) project take place?
The project location(s) are: United States.
How can I apply for Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)?
Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.